These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
643 related articles for article (PubMed ID: 24740824)
1. Teriflunomide and its mechanism of action in multiple sclerosis. Bar-Or A; Pachner A; Menguy-Vacheron F; Kaplan J; Wiendl H Drugs; 2014 Apr; 74(6):659-74. PubMed ID: 24740824 [TBL] [Abstract][Full Text] [Related]
2. Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects. Klotz L; Eschborn M; Lindner M; Liebmann M; Herold M; Janoschka C; Torres Garrido B; Schulte-Mecklenbeck A; Gross CC; Breuer J; Hundehege P; Posevitz V; Pignolet B; Nebel G; Glander S; Freise N; Austermann J; Wirth T; Campbell GR; Schneider-Hohendorf T; Eveslage M; Brassat D; Schwab N; Loser K; Roth J; Busch KB; Stoll M; Mahad DJ; Meuth SG; Turner T; Bar-Or A; Wiendl H Sci Transl Med; 2019 May; 11(490):. PubMed ID: 31043571 [TBL] [Abstract][Full Text] [Related]
3. Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells. Tilly G; Cadoux M; Garcia A; Morille J; Wiertlewski S; Pecqueur C; Brouard S; Laplaud D; Degauque N Front Immunol; 2021; 12():730342. PubMed ID: 34721394 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review. Kaur H; Sarma P; Bhattacharyya A; Sharma S; Chhimpa N; Prajapat M; Prakash A; Kumar S; Singh A; Singh R; Avti P; Thota P; Medhi B Eur J Pharmacol; 2021 Sep; 906():174233. PubMed ID: 34111397 [TBL] [Abstract][Full Text] [Related]
5. Teriflunomide for multiple sclerosis. He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123 [TBL] [Abstract][Full Text] [Related]
6. Teriflunomide for multiple sclerosis. He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682 [TBL] [Abstract][Full Text] [Related]
7. [Teriflunomide (Aubagio). New treatment for multiple sclerosis]. Sabourin G Perspect Infirm; 2014; 11(3):56. PubMed ID: 24855766 [No Abstract] [Full Text] [Related]
8. Teriflunomide attenuates neuroinflammation-related neural damage in mice carrying human PLP1 mutations. Groh J; Hörner M; Martini R J Neuroinflammation; 2018 Jul; 15(1):194. PubMed ID: 29970109 [TBL] [Abstract][Full Text] [Related]
9. Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients. Medina S; Sainz de la Maza S; Villarrubia N; Álvarez-Lafuente R; Costa-Frossard L; Arroyo R; Monreal E; Tejeda-Velarde A; Rodríguez-Martín E; Roldán E; Álvarez-Cermeño JC; Villar LM Ann Clin Transl Neurol; 2019 Feb; 6(2):355-363. PubMed ID: 30847367 [TBL] [Abstract][Full Text] [Related]
10. Teriflunomide: A Review in Relapsing-Remitting Multiple Sclerosis. Scott LJ Drugs; 2019 Jun; 79(8):875-886. PubMed ID: 31098896 [TBL] [Abstract][Full Text] [Related]
11. The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro. Li L; Liu J; Delohery T; Zhang D; Arendt C; Jones C J Neuroimmunol; 2013 Dec; 265(1-2):82-90. PubMed ID: 24182769 [TBL] [Abstract][Full Text] [Related]
12. Spotlight on teriflunomide. Tallantyre E; Evangelou N; Constantinescu CS Int MS J; 2008 Jun; 15(2):62-8. PubMed ID: 18782502 [TBL] [Abstract][Full Text] [Related]
13. Teriflunomide (Aubagio®) for the treatment of multiple sclerosis. Bar-Or A Exp Neurol; 2014 Dec; 262 Pt A():57-65. PubMed ID: 24925677 [TBL] [Abstract][Full Text] [Related]
14. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year. Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986 [TBL] [Abstract][Full Text] [Related]
15. Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry. Papp V; Buron MD; Siersma V; Rasmussen PV; Illes Z; Kant M; Hilt C; Mezei Z; Roshanisefat H; Sejbæk T; Weglewski A; van Wingerden J; Geertsen SS; Bramow S; Sellebjerg F; Magyari M PLoS One; 2021; 16(5):e0250820. PubMed ID: 34003862 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study. Miller AE; Xu X; Macdonell R; Vucic S; Truffinet P; Benamor M; Thangavelu K; Freedman MS J Clin Neurosci; 2019 Jan; 59():229-231. PubMed ID: 30348586 [TBL] [Abstract][Full Text] [Related]
17. Teriflunomide: a review of its use in relapsing multiple sclerosis. Garnock-Jones KP CNS Drugs; 2013 Dec; 27(12):1103-23. PubMed ID: 24198223 [TBL] [Abstract][Full Text] [Related]
18. A novel series of teriflunomide derivatives as orally active inhibitors of human dihydroorotate dehydrogenase for the treatment of colorectal carcinoma. Li C; Zhou Y; Xu J; Zhou X; Huang Z; Zeng T; Yang X; Tao L; Gou K; Zhong X; Chen Q; Luo Y; Zhao Y Eur J Med Chem; 2022 Aug; 238():114489. PubMed ID: 35640328 [TBL] [Abstract][Full Text] [Related]
19. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases. Fragoso YD; Brooks JB Expert Rev Clin Pharmacol; 2015 May; 8(3):315-20. PubMed ID: 25712857 [TBL] [Abstract][Full Text] [Related]
20. Teriflunomide for the treatment of multiple sclerosis. Warnke C; Stüve O; Kieseier BC Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S90-4. PubMed ID: 24321165 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]